Celcuity公司宣布,其Viktoria-1三期临床试验在Pik3CA突变患者队列中成功达成主要研究终点。试验数据显示,该队列患者的无进展生存期实现了具有临床意义的显著改善。
Celcuity公司宣布,其Viktoria-1三期临床试验在Pik3CA突变患者队列中成功达成主要研究终点。试验数据显示,该队列患者的无进展生存期实现了具有临床意义的显著改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.